Get Level 2

SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Rtw Biotech Share Price
  4. Rtw Biotech Share Regulatory News
  5. Spectris

Pin to quick picksRtw Biotech Regulatory News (RTW)

Rtw Biotech Information

Share Price Information for Rtw Biotech (RTW)

Share Price is delayed by 15 minutes
Get Live Data
2.21    0.00 (0.00%)
Bid:
2.19
Ask:
2.21
Spread: 0.02 (0.913%)
Market Cap: $714.60m
RTW Live PriceLast checked at - London Stock Exchange

Intraday Rtw Biotech Share Chart

Spectris

1 Dec 2025 18:00

RNS Number : 7232J
FTSE Russell
01 December 2025
 

 

 

Further to the FTSE Russell notice released on 25 November 2025 in relation to Spectris (UK): Constituent Deletion, please note the FTSE 250 Index replacement and associated changes.

 

All other details remain unchanged. Please see updated notice below:

Spectris (UK): Constituent Deletion - UpdateChanges in FTSE UK Index Series

01 December 2025

Subject to court sanctioning the scheme of arrangement for the cash offer for Spectris (UK, constituent) by Aurora Bidco Limited (non-constituent), please see details of affected indexes and effective dates below:

 

Spectris (UK, 0330860) will be deleted from the FTSE 250 Index.

 

RTW Biotech Opportunities (UK, BKTRRM2) will be added to the FTSE 250 Index and deleted from the FTSE SmallCap Index.

 

All changes effective from the open of Thursday 04 December 2025.

 

Full details of changes are available on the FTSE Russell website.

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+61 (0) 2 7228 5659

Hong Kong

+852 2164 3333

Japan

+81 3 6441 1430

London

+44 (0) 20 7866 1810

New York

+1877 503 6437

Alternatively please visit our website at lseg.com/ftse-russell

Terms of Use | Copyright © 2025 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FTSTBBJTMTMMBIA
12345678910
Date   Source Headline
30th Apr 20257:00 amRNSJade Biosciences merges with Aerovate Therapeutics
29th Apr 20257:00 amRNSTransaction in Own Shares
28th Apr 20257:00 amRNSTransaction in Own Shares
25th Apr 20257:00 amRNSTransaction in Own Shares
22nd Apr 20257:00 amRNSTransaction in Own Shares
17th Apr 20251:30 pmRNSAnnual Financial Report
16th Apr 20257:00 amRNSTransaction in Own Shares
14th Apr 20257:01 amRNSTransaction in Own Shares
14th Apr 20257:00 amRNSMonthly Valuation Update and Factsheet
10th Apr 202512:30 pmRNSDirector/PDMR Shareholding
10th Apr 20257:00 amRNSTransaction in Own Shares
9th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSTransaction in Own Shares
3rd Apr 202512:30 pmRNSNew Investment in AIRNA
2nd Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20257:00 amRNSTotal Voting Rights
31st Mar 20257:00 amRNSAnnual Financial Report
28th Mar 20257:00 amRNSTransaction in Own Shares
26th Mar 20257:00 amRNSTransaction in Own Shares
21st Mar 20257:00 amRNSTransaction in Own Shares
20th Mar 20257:00 amRNSTransaction in Own Shares
14th Mar 20257:01 amRNSTransaction in Own Shares
14th Mar 20257:00 amRNSMonthly Valuation Update and Factsheet
13th Mar 20257:00 amRNSTransaction in Own Shares
10th Mar 20257:00 amRNSNotice of Annual Results
7th Mar 20257:00 amRNSTransaction in Own Shares
26th Feb 20257:00 amRNSRTW CIO increases position to 15%
25th Feb 20251:00 pmRNSMaterial purchase by CIO of the Investment Manager
17th Feb 20257:00 amRNSDirector/PDMR Shareholding
14th Feb 20257:00 amRNSMonthly Valuation Update and Factsheet
28th Jan 20257:00 amRNSMaterial Update from Portfolio Company
27th Jan 20257:00 amRNSKailera Reports Positive Data in Ph2 Obesity Trial
17th Jan 20257:01 amRNSNew Investment in Series A of Windward Bio
17th Jan 20257:00 amRNSAdditional Investment in Umoja Biopharma
15th Jan 20257:00 amRNSMonthly Valuation Update and Factsheet
14th Jan 20257:00 amRNSAdditional Investment in Numab Therapeutics
10th Jan 20257:00 amRNSNew Investment in Series A of Alesta Therapeutics
30th Dec 20247:00 amRNSCORXEL Announces Two Significant Transactions
20th Dec 202412:15 pmRNSNew Investment in Series A of Ottimo Pharma
13th Dec 20247:00 amRNSMonthly Valuation Update and Factsheet
10th Dec 202412:00 pmRNSHolding(s) in Company
10th Dec 20247:00 amRNSAppointment of Senior Independent Director
15th Nov 20247:00 amRNSCORXEL Announces Acceptance of NDA for Aficamten
14th Nov 20247:00 amRNSMonthly Valuation Update and Factsheet
1st Nov 20242:00 pmRNSNew Investment in Series C Round of Evommune, Inc.
1st Nov 20247:00 amRNSRTW Biotech Opportunities’ 5th Anniversary
14th Oct 20246:12 pmRNSMonthly Valuation Update and Factsheet Replacement
14th Oct 20247:00 amRNSMonthly Valuation Update and Factsheet
3rd Oct 20247:00 amRNSLaunch of Obesity Company Kailera Therapeutics
2nd Oct 20247:00 amRNSNew Investment in Aktis Oncology
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
XO50
Snb Fund.27
LSE
0.00%
OI38
Citi Fun 26
LSE
0.00%
SLS
SLS.L
LSE
0.00%
WP60
Citi Fun 36
LSE
0.00%
BF76
Ex-im Korea 27
LSE
0.00%
Trending
IMM
Immupharma
LSE
5.42%
AVCT
Avacta Group
LSE
3.65%
GGP
Greatland Resources
LSE
8.70%
PREM
Premier African Minerals
LSE
4.88%
RR.
Rolls-Royce
LSE
4.41%